June 18, 2021
1 min read
Save
Eight important updates for World Sickle Cell Day
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
World Sickle Cell Day is observed each year on June 19.
The observation is intended to raise awareness of sickle cell disease, as well as the challenges patients encounter.
In conjunction with this weekend’s World Sickle Cell Day observation, Healio and HemOnc Today present the following important updates in sickle cell disease treatment and research.
- Pregnant women with sickle cell disease who had poor baseline gestational pulmonary function had significantly greater risk for fetal death. Read more.
- Three patients with sickle cell disease who received the investigational gene therapy ARU-1801 (Aruvant Sciences) achieved and maintained normal hemoglobin levels. The findings showed successful engraftment of the autologous gene therapy after reduced-intensity conditioning with melphalan. Read more.
- The FDA approved deferiprone (Ferriprox, Chiesi Farmaceutici) for treatment of children or adults with transfusional iron overload due to sickle cell disease or other anemias. The indication applies to use of the agent for patients aged 3 years or older. Read more.
- Patients with sickle cell disease-related kidney failure experienced similar reductions in mortality following transplantation as those whose kidney failure stemmed from other causes. Read more.
- The use of gene-edited stem cells has shown early positive results among patients with sickle cell disease and transfusion-dependent beta-thalassemia. Read more.
- Patients with sickle cell disease may be at higher risk for certain COVID-19 complications and death. Read more.
- Toxicity on spermatogenesis may not be a major concern for boys with severe sickle cell disease who require hydroxyurea treatment before puberty. The effect of hydroxyurea exposure on infants, however, remains unknown. Read more.
- ASH issued new evidence-based guidelines for sickle cell disease, with the goal of helping providers and patients make informed decisions regarding individualized care. Read more.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Reporting
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.